Amygdalar activity measured using FDG-PET/CT at head and neck cancer staging independently predicts survival.
Malek Z O HassanAhmed TawakolYing WangRaza M AlviMagid AwadallaMaeve Jones-O'ConnorRula B BakarDahlia BanerjiAdam RokickiLili ZhangConnor P MulliganMichael T OsborneAzmaeen ZarifBasma HammadAnnie W ChanLori J WirthErica T WarnerRoger K PitmanKatrina A ArmstrongDaniel AddisonTomas G NeilanPublished in: PloS one (2023)
AmygA, quantified on routine 18F-FDG-PET/CT images obtained at cancer staging, independently and robustly predicts mortality and cancer progression among patients with HNCA. Future studies should test whether strategies that attenuate AmygA (or its downstream biological consequences) may improve cancer survival.